Answers are grounded in this paper and cite their sources.
Background: The inhibition of matrix metalloproteinases and IgE could be a prospective target of treating inflammation and remodelling of asthma. Doxycycline, a known antibiotic may qualify for the job for having both the properties. Objective: To look for effect on long term add-on oral doxycycline in patients of asthma. Methods: In an open prospective, real-world observation, a cohort of asthmatics was given to choose treatment either with a “standard” therapy (long-acting β-2 agonist + inhaled corticosteroid) or with the same and add-on long term doxycycline orally. The changes in postbronchodilator FEV 1 , FEV 1 /FVC, and FEF 25–75 were noted for comparison with repeat spirometry after nearly a year. Results: The two groups (standard therapy alone [ n = 73] and standard therapy plus doxycycline [ n = 72]) were similar ( p < 0.05) as regards to age and BMI, but the subjects opting for add-on doxycycline had significantly lower baseline postbronchodilator FEV 1 (1.25 ± 0.50 and 1.66 ± 0.73 Litres; p < 0.0001). Both the groups had received treatment for similar length of time (346.89 ± 269.61 and 335.82 ± 274.51 days, respectively). The add-on doxycycline group had a significant improvement in absolute value of postbronchodilator FEV 1 (130 mL [ p = 0.0000]), whereas the subjects on standard therapy alone showed a reduction (70 mL [ p = 0.027]) compared to the baseline values. There was a parallel increase in FEV 1 /FVC ( p < 0.005) and FEF 25-75 ( p < 0.0001) in the doxycycline-treated patients, suggesting an overall improvement in airflow limitations. Conclusion: The add-on oral doxycycline tolerated well on long term and resulted in a significant improvement in spirometric indices of airflow limitations in the asthmatics. The observation deserves further validation.
No takes yet. Share an insight, caveat, or question.
Bhattacharyya et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: